Efficacy of alogliptin combined with motor imagery under hyperbaric oxygen in diabetic nephropathy with silent cerebral infarction

Abstract

In the present study, we evaluated the curative effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor alogliptin combined with motor imagery under hyperbaric oxygen in diabetic nephropathy (DN) with silent cerebral infarction (SCI). Two-hundred newly diagnosed DN patients with and without SCI were included. The SCI patients were divided into two treatment groups: Alogliptin (A group, n=50) and alogliptin combined with motor imagery under hyperbaric oxygen (B group, n=50). The degrees of neurocognitive dysfunction were evaluated at baseline and after 6 months of treatment. Thromboelastograms (TEGs) mapping were conducted. Serum glycoprotein VI (GPVI) mRNA expression and urine 11-DH-TXB2 levels were determined. Compared to group A patients, the severity of neurofunctional defects, GPVI mRNA expression and 11-DH-TXB2 levels were significantly lower in group B (P<0.05), while comprehensive, MoCA scores were higher in group B. The MoCA subscores of visuospatial/executive function, attention and concentration were significantly higher compared to group A (P<0.05). The sub-scores of computation, abstract thinking, language competence, memory and orientation were also higher in group B but the differences were not significant (P>0.05). TEG indexes were improved in both groups after treatment as manifested by increased R and K values, but there was significant improvement in group B. Intra-group comparisons revealed a time-dependent effect of treatment. In conclusion, the treatment of alogliptin combined with motor imagery under hyperbaric oxygen can better promote thrombolysis absorption, restore brain damage and improve neurocognitive function in DN with silent cerebral infarction.

Antidiabetic treatment on memory and spatial learning: From the pancreas to the neuron

“…In a mice model of middle cerebral artery occlusion, the treatment group mediated the results of tissue ischemia and restored the defects of the blood brain barrier via altering the expression patterns of metalloproteinases and their inhibitors along with occludin and zona occludens-1 proteins[ 45 ]. On another model of diabetic nephropathy with silent cerebral infracts, the combination of alogliptin and hyperbaric oxygen treatment had a beneficial restorative effect on neural function[ 46 ]. Additionally, on high-fat fed doubly-negative apolipoprotein E mice with resultant cognitive decline, alogliptin up-regulated BDNF and calcineurin hippocampal production with accompanying higher performance on MWM and novel object recognition test than controls[ 47 ].…”

An observation of the clinical efficacy of combining Riluzole with mannitol and hyperbaric oxygen in treating acute spinal cord injury

“…However, conventional oxygen inhalation cannot eliminate such pathological changes as anoxia and edema of spinal cord, thus it is of limited help in improving the prognosis. 15,16 Hyperbaric oxygen therapy is highly valued in dealing with nerve injury. 17 BDNF and BFGF in serum can reflect the severity of nerve damage.…”

Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs

“…Имеются данные экспериментальных и клинических исследований, что некоторые ингибиторы ДПП-4, особенно ситаглиптин, имеют положительное влияние на когнитивные функции [94][95][96][97][98][99][100][101].…”

“…Chen и соавт. [99] изучали влияние еще одного представителя класса ингибиторов ДПП-4 -алоглиптина на когнитивные функции у 100 пациентов с диабетической нефропатией и наличием, по данным магнитно-резонансной томографии, так называемых «немых» инфарктов головного мозга. Через 6 мес лечения алоглиптином авторы отметили статистически значимое увеличение интегрального показателя когнитивных функций по тесту MoCA, что может свидетельствовать о положительном влиянии алоглиптина на интеллект больных СД2.…”